FibroBiologics, Inc. Common Stock (FBLG) — Financial statements
Income statement, balance sheet, and cash flow for FibroBiologics, Inc. Common Stock — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 0.83 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | -0.83 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 7↑64.5% | 5↑90.2% | 2↑106.5% | 1↑120.2% | 0.52 | |
| General & Administrative Expenses | 9↑0.1% | 9↑41.6% | 7↑96.4% | 3↑214.1% | 1 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 9↑0.1% | 9↑41.6% | 7↑96.4% | 3↑214.1% | 1 | |
| Other Expenses | -0.83 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 16↑15.1% | 14↑54.5% | 9↑99.0% | 4↑183.1% | 2 | |
| Total Costs & Expenses | 17↑21.2% | 14↑54.5% | 9↑99.0% | 4↑183.1% | 2 | |
| Operating Results | ||||||
| Operating Income | -17↓21.2% | -14↓54.5% | -9↓99.0% | -4↓183.1% | -2 | |
| Depreciation & Amortization | 0.83↑45.2% | 0.57↑31.1% | 0.44↑364.9% | 0.09 | 0.00 | |
| EBITDA | -18↓66.6% | -11↑33.5% | -16↓263.6% | -4↓177.1% | -2 | |
| EBIT | -18↓65.5% | -11↑31.8% | -16↓265.7% | -4↓183.1% | -2 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.04↓81.4% | 0.23↑257.1% | -0.15↑77.5% | -0.65↓16250.0% | -0.00 | |
| Interest Income | 0.25↓1.6% | 0.25 | 0.00 | 0.00 | 0.00 | |
| Interest Expense | 0.20↑920.0% | 0.02↓86.4% | 0.15↓77.5% | 0.65↑16250.0% | 0.00 | |
| Non-Operating Income | 2↑169.1% | -3↓134.9% | 7 | 0.00 | 0.00 | |
| Other Income / Expenses | -2↓177.5% | 3↑133.9% | -8↓1061.5% | -0.65↓16250.0% | -0.00 | |
| Income Before Tax | -19↓67.1% | -11↑32.3% | -16↓221.9% | -5↓223.7% | -2 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -19↓67.1% | -11↑32.3% | -16↓221.9% | -5↓223.7% | -2 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -19↓67.1% | -11↑32.3% | -16↓221.9% | -5↓223.7% | -2 | |
| Bottom-Line Net Income | -19↓67.1% | -11↑41.4% | -19↓272.2% | -5↓223.7% | -2 | |
| EPS (Basic) | -8.40↓23.5% | -6.80↑42.4% | -11.80↓268.8% | -3.20↓228.5% | -0.97 | |
| EPS (Diluted) | -8.40↓23.5% | -6.80↑42.4% | -11.80↓268.8% | -3.20↓228.5% | -0.97 | |
| Weighted Average Shares | 2↑35.8% | 2↑1.2% | 2↑0.0% | 2↑0.0% | 2 | |
| Weighted Average Diluted Shares | 2↑35.8% | 2↑1.2% | 2↑0.0% | 2↑0.0% | 2 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.